ARTICLE | Finance
Hat trick for Versant as Graphite follows Monte Rosa, Century to NASDAQ
Firm’s portfolio companies quickly lining up to tap biotech’s yawning IPO window
June 25, 2021 2:25 AM UTC
With Monte Rosa and Graphite Bio pricing IPOs late this week, a trio of companies backed by Versant have completed offerings valuing each at more than $850 million in the span of a few days.
Graphite Bio Inc. (NASDAQ:GRPH), Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) and Century Therapeutics Inc. (NASDAQ:IPSC) raised a total of $703 million with postmoney valuations of $850 million-$1.1 billion. Versant holds stakes of at least 20% in all three...